Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
Identifieur interne : 002936 ( PubMed/Corpus ); précédent : 002935; suivant : 002937Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
Auteurs : J. Lisziewicz ; D. Sun ; M. Klotman ; S. Agrawal ; P. Zamecnik ; R. GalloSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1992.
English descriptors
- KwdEn :
- Base Sequence, Cell Survival (drug effects), Cells, Cultured, HIV-1 (genetics), HIV-1 (growth & development), Humans, In Vitro Techniques, Molecular Sequence Data, Mutation, Oligonucleotides, Antisense (chemistry), Oligonucleotides, Antisense (pharmacology), Time Factors, Virus Replication (drug effects).
- MESH :
- chemical , chemistry : Oligonucleotides, Antisense.
- drug effects : Cell Survival, Virus Replication.
- genetics : HIV-1.
- growth & development : HIV-1.
- chemical , pharmacology : Oligonucleotides, Antisense.
- Base Sequence, Cells, Cultured, Humans, In Vitro Techniques, Molecular Sequence Data, Mutation, Time Factors.
Abstract
We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.
DOI: 10.1073/pnas.89.23.11209
PubMed: 1454800
Links to Exploration step
pubmed:1454800Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</title>
<author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J" last="Lisziewicz">J. Lisziewicz</name>
<affiliation><nlm:affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D" last="Sun">D. Sun</name>
</author>
<author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M" last="Klotman">M. Klotman</name>
</author>
<author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S" last="Agrawal">S. Agrawal</name>
</author>
<author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P" last="Zamecnik">P. Zamecnik</name>
</author>
<author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R" last="Gallo">R. Gallo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1454800</idno>
<idno type="pmid">1454800</idno>
<idno type="doi">10.1073/pnas.89.23.11209</idno>
<idno type="wicri:Area/PubMed/Corpus">002936</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002936</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</title>
<author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J" last="Lisziewicz">J. Lisziewicz</name>
<affiliation><nlm:affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D" last="Sun">D. Sun</name>
</author>
<author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M" last="Klotman">M. Klotman</name>
</author>
<author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S" last="Agrawal">S. Agrawal</name>
</author>
<author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P" last="Zamecnik">P. Zamecnik</name>
</author>
<author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R" last="Gallo">R. Gallo</name>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Base Sequence</term>
<term>Cell Survival (drug effects)</term>
<term>Cells, Cultured</term>
<term>HIV-1 (genetics)</term>
<term>HIV-1 (growth & development)</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Molecular Sequence Data</term>
<term>Mutation</term>
<term>Oligonucleotides, Antisense (chemistry)</term>
<term>Oligonucleotides, Antisense (pharmacology)</term>
<term>Time Factors</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Oligonucleotides, Antisense</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Survival</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>HIV-1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligonucleotides, Antisense</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term>
<term>Cells, Cultured</term>
<term>Humans</term>
<term>In Vitro Techniques</term>
<term>Molecular Sequence Data</term>
<term>Mutation</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1454800</PMID>
<DateCompleted><Year>1993</Year>
<Month>01</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>05</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print"><Volume>89</Volume>
<Issue>23</Issue>
<PubDate><Year>1992</Year>
<Month>Dec</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.</ArticleTitle>
<Pagination><MedlinePgn>11209-13</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lisziewicz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Klotman</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agrawal</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zamecnik</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gallo</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>A1-24846</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30-12708-17</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year>
<Month>12</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1992</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1992</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1454800</ArticleId>
<ArticleId IdType="pmc">PMC50519</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.89.23.11209</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cell. 1990 Nov 2;63(3):601-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2225067</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1990 Jun;87(12):4571-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2191294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1990 Feb 23;60(4):675-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2406030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Natl Cancer Inst. 1987 Apr;78(4):663-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2435942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2471199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1985 Jan 24-30;313(6000):277-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2578615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):7790-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2682627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1985 Jul 5;229(4708):69-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2990040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jun;83(12):4143-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3012555</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1988 Aug;85(15):5507-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3041414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1988 Oct;85(19):7079-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3174622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1988 Oct;85(20):7448-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3174646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biochem Biophys Methods. 1986 Sep;13(2):97-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3772027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1984 May 4;224(4648):497-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6200935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gene. 1988 Dec 10;72(1-2):343-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3243433</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Biotechnol. 1992 May;10(5):152-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1368317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1992 Jan;66(1):600-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1727504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):758-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1731351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1991 Apr 19;65(2):241-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2015625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 1991 Jun 25;19(12):3359-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2062653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1990 Nov 25;265(33):20172-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2173699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1990 Jun 29;61(7):1271-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2364429</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002936 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002936 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:1454800 |texte= Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1454800" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |